#ACR21 Abst#0801 Early remission at 6 mos is a predictor of long-term remission in patients w new onset RA ▶️ DAS28-CRP, SDAI, CDAI at 6mo predicted remission at 60 months https://t.co/vWy7EmseZp @Rheumnow https://t.co/HWJSjvFY8d

• https://bit.ly/3CSPFNr

How can we better identify patients with #RA-ILD using #EHRs? Abs#0561: previously validated algorithms have clinical & research utility when applied to EHRs, esp when well-integrated with key info such as CT chest reports #ACR21 @RheumNow https://t.co/OU8BdwqHpc

• Enhancing the Identification of Rheumatoid Arthritis-Associated Interstitial Lu…

ADACTA & MONARCH both showed IL6i monoRx > TNFi monoRx for RA in DBRCTs. What about in real-world data? Looking at CorEvitas, less so LDA: aOR 0.99 MCID in CDAI: 1.06 Even without MTX, both great drug classes for RA Equally so? #ACR21 ABST0834 @RheumNow https://t.co/6wvzVrXTW6 https://t.co/fYEktJhZuV

• https://meet.acrconvergence.org/meetings/virtual/dSEeRFsuxifj8bZbz

#ACR21 A#0563 - Is FRAX score applicable for RA? 10 yr Olmsted County epi study: Yes ▶️ 76 osteoporotic fxs in RA pts, FRAX predicted 67 fx (SIR 1.13, not signif) ▶️ 21 observed hip fx, FRAX predicted 23.3 (SIR 0.9) ⭐️ No differences by ages/sex https://t.co/vWy7EmseZp @Rheumnow https://t.co/8BlzgQYqaV

• https://bit.ly/3CSPFNr

Guidance on self-efficacy (SE) in IA were published this yr- what factors influence this? 👉PROMs & treatment response determine long-term SE 👉This may help identify pts benefitting most from interventions to improve SE Abs#0795 #ACR21 @RheumNow https://t.co/dx28WgxNsE https://t.co/7uN6XctnQb

• Treatment Response and Several Patient-reported Outcomes Are Early Determinants…

#ACR21 Abst#0786. Fibroscan screening for liver injury in pts on MTX: ▶️No significant correlation between cumulative MTX dose and liver stiffness by fibroscan, even at high dose MTX. ⭐️Age, sex, waist circumference, BMI are risks @Rheumnow https://t.co/IhcNr9fhEh https://t.co/c7TUoGrNZ7

• https://bit.ly/3bLe4Jb

It was a pleasure to speak to Dr Bryant England about #multimorbidity in #rheumatoidarthritis with a focus on abstract #1924, to be presented at the #Epidemiology & #PublicHealth abstract session on Tuesday #ACR21: https://t.co/qHws6B3fFf Watch @RheumNow: https://t.co/OKM7WxIEpR

• Patient Clustering Based on Multimorbidity Patterns Predicts Healthcare Utiliza…
• Patient Clustering Based on Multimorbidity Patterns in RA: Dr. Mrinalini Dey an…

#ACR21 Abst#0285 Calculated 10-yr CV risk ↑ w/in 1st yr of new RA dx in 53 Dutch pts: ➤43% had intermediate (I) or high (H) morbidity risk ➤76% had I or H mortality risk ◘ avg 57yo, 74%♀, 72% HTN, & 57% HLD *️⃣ Early CV risk assessment critical at RA diagnosis! @Rheumnow